Compare iShares Core Growth Allocation ETF (AOR) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Johnson & Johnson — how do they compare? iShares Core Growth Allocation ETF trades at $70.5, while Johnson & Johnson trades at $261.31 (market cap $628.65B). The key difference: Johnson & Johnson pays a 2.05% dividend while iShares Core Growth Allocation ETF pays none, and iShares Core Growth Allocation ETF is trading nearer its 52-week high, Johnson & Johnson nearer its low. Which is the better fit depends on your goals.
| AOR | JNJ | |
|---|---|---|
52-Week High | $70.12 | $267.24 |
52-Week Low | $62.26 | $174.16 |
Market Cap | — | $628.65B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $656.92B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, the iShares Core Growth Allocation ETF, trades at $70.11, up 0.27% on the day. Technical indicators show a bullish trend with strong moving average signals, though the RSI suggests potential overbought conditions. The ETF maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low expense ratio of 0.20%.
The outlook for AOR is mixed; it offers diversified exposure and cost efficiency, but has underperformed the S&P 500 over the past decade. Key risks include market volatility and allocation strategy limitations. Analyst sentiment is generally positive for long-term core holdings.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
